Kipferon® (Kipferon®)

Composition Pharmacodynamics Indications Carefully Contraindications Dosing and Administration Side effects Form release / dosage
Read on
Similar drugsTo uncover
Dosage form: & nbspVaginal and rectal suppositories
Composition:

For one suppository:

Active substances:

immunoglobulin complex preparation (TRC)

0.2 g

interferon alfa-2b human,

recombinant

500000 ME

Excipients:

fat special purpose "SolPro" confectionary for chocolate products and sweets

0.838 g

paraffin oil hard P-2

0.085 g

emulsifier "Hard" (T-2)

0.085 g

sodium dodecahydrate hydrophosphate

0,055mg

sodium dihydrogen phosphate dihydrate

0.018 mg

sodium chloride

0.110 mg

purified water

0.012 g
Description:

Suppositories white, white with a yellowish tinge or light beige color, with a characteristic odor, cylindrical shape with a pointed end, on the longitudinal section are uniform.

On the cut, an air rod or a funnel-shaped depression is allowed. Color heterogeneity in the form of marble is allowed.

Pharmacotherapeutic group:MIBP-cytokine
ATX: & nbsp
  • Anti-inflammatory drugs for intravaginal application
    • Pharmacodynamics:

    pharmachologic effect

    - immunomodulating;

    - antiviral;

    - antichlamydial.

    Pharmacological properties

    Suppositories Kipferon® is a complex dosage form containing human recombinant interferon-α2 and a complex immunoglobulin preparation (CIP).

    Interferon-α2 is an activator of congenital and acquired immunity, has a pronounced antiviral activity, enhances protection against viral, chlamydial, mycoplasma and bacterial infections, has an immunomodulating effect in the development of immunological reactions, promotes the growth and preservation of the normoflora of the intestine and vagina.

    The biological activity of interferon-α2 is realized through interaction with the receptor apparatus of immunocompetent and other cells, leading to increased expression of molecules HLAI and HLAII on the surface of all cell types and the regulation of cell cooperation, increase the activity of natural killers, and also give intact cells resistance against their cytolytic action, proliferation CD8 T cells.

    Increases the production of gamma-interferon by natural killers.

    Complex immunoglobulin preparation of instrumentation contains specific and nonspecific immunoglobulins of classes G, M, A. The combination of antiviral, antichlamydia, antibacterial and antitoxic antibodies belonging to different classes of immunoglobulins provides agglutination, neutralization and precipitation of etiotropic pathogenic agents.In the place of application it provides stabilization of interferon from secrets of mucous membranes, normalizes local immunity due to the intake of IgA and IgM with suppositories (a substitution effect), increases the activity of locally formed cytokines.

    Indications:

    The drug is used in the complex therapy of diseases accompanied by secondary immunodeficiency states:

    - acute respiratory infections, inflammatory diseases of the oropharynx of bacterial and viral etiology in children and adults;

    - acute viral (rotavirus) and bacterial (salmonellosis, dysentery, coli-infection), intestinal infections, including manifestations of intestinal dysbiosis of different severity in children;

    - urogenital chlamydia in women (including pregnant women in the II-III trimesters of pregnancy), including manifestations of dysbacteriosis of the vagina, vulvovaginitis, cervicitis of the uterus, erosion of the cervix.

    Contraindications:

    Individual intolerance of individual components, pregnancy I trimester, lactation.

    Dosing and Administration:

    Kipferon® is applied rectally and vaginally.The drug is used in conjunction with conventional means of pathogenetic therapy of infectious diseases, as well as antibiotics according to indications.

    The method and dosage regimen, as well as the use in complex treatment, is determined by the doctor depending on the diagnosis, severity and severity of the disease.

    Acute respiratory diseases, inflammatory diseases of the oropharynx of bacterial and viral etiology: Suppositories are administered rectally (mainly after the act of defecation) to children under 1 year of one suppository per day, children under 12 years - 1 suppository twice a day, adults and children over 12 years 1 suppository three times a day.

    The most effective and appropriate administration of Kipferon® in the acute period of the disease (preferably in the first 3 days). The duration of treatment is determined by etiology, the severity of the disease, the presence of concomitant complications, pathological conditions and is 5-7 days.

    Acute viral (rotavirus) and bacterial (salmonellosis, dysentery, coli infection), intestinal infections, including manifestations of intestinal dysbiosis of different severity in children: Suppositories are administered rectally (mainly after the act of defecation) to children under 1 year of one suppository per day, children under 12 years - 1 suppository twice a day, adults and children over 12 years - 1 suppository three times a day. The most effective and appropriate use of the drug in the acute period of the disease (preferably in the first 3 days). The duration of treatment is determined by etiology, the severity of the disease, the presence of concomitant complications, pathological conditions and is 5-7 days.

    Urogenital chlamydia in women (including pregnant women in the II-III trimesters of pregnancy), including those with vaginal dysbacteriosis, vulvovaginitis, cervicitis of the uterus, cervical erosion: suppositories are injected deeply intravaginally (before contact with the posterior vaginal vault and cervix) for 1-2 suppositories, depending on the severity of the disease, twice a day. The course of treatment is an average of 10 days; in the presence of erosion of the cervix, the drug is continued until it is epithelialized. According to the indications, the course of treatment can be repeated in one month. Treatment should begin in the first days after the end of menstruation.Before administration, it is recommended to remove mucus from the mucous membranes of the vagina and cervix.

    Side effects:

    Not registered.

    Overdose:

    Cases of drug overdose are not known.

    Interaction:

    Negative effects on other drugs have not been observed.

    Effect on the ability to drive transp. cf. and fur:

    When used in recommended doses, the drug does not affect the behavior or functional indices of the body, nor does it affect the ability to drive vehicles and mechanisms.

    Form release / dosage:Suppositories for vaginal or rectal administration.
    Packaging:

    There are 5 suppositories in a contiguous cell package.

    2 contour squares with instructions for use in a pack of cardboard.

    Storage conditions:Store at temperatures from 2 to 8 ° C, out of the reach of children.
    Shelf life:

    1 year.

    Do not use after the time specified on the package.

    Terms of leave from pharmacies:Without recipe
    Registration number:P N000126 / 01
    Date of registration:28.02.2011 / 02.11.2017
    Expiration Date:Unlimited
    The owner of the registration certificate:ALFARM, LLC ALFARM, LLC Russia
    Manufacturer: & nbsp
    Information update date: & nbsp08.01.2018
    Illustrated instructions
      Instructions
      Up